"ShangPharma Innovation And Icahn School Of Medicine At Mount Sinai Forge Translational Research Collaboration"
ShangPharma Innovation Inc., a global venture capital firm focused on biomedical R&D therapeutics and technologies, and the Icahn School of Medicine at Mount Sinai has entered into a multi-year strategic collaboration to accelerate the development of novel early-stage therapeutics. ShangPharma Innovation will provide funding and preclinical research support to further the Icahn School of Medicine at Mount Sinai's objectives of validating drug targets and establishing programs to discover new therapies. "This partnership was fueled by the groundbreaking technologies from innovators here at Mount Sinai. Our expertise in commercially-relevant translational research, coupled with ShangPharma Innovation's drug development capabilities will advance much needed medicines to patients worldwide," said Erik Lium, PhD, senior vice president of Mount Sinai Innovation Partners at the Icahn School of Medicine at Mount Sinai.
- Erik Lium, PhD, Senior Vice President, Mount Sinai Innovation Partners, Icahn School of Medicine at Mount Sinai